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Background 
 Granulosa cell tumors (GCTs) are the most 
common form of ovarian neoplasm in mares, 
accounting for more than 85% of all tumors of the 
reproductive tract in female horses.1 
Histopathologically, GCTs are sex cord-stromal 
tumors that may be comprised primarily of 
granulosa cells or a mixture of granulosa and thecal 
cells. There is no breed or age predilection for 
GCTs in mares, and although most GCTs are 
diagnosed in sexually mature mares, they have also 
been diagnosed in prepuberal fillies. In adult horses, 
GCTs have been diagnosed in maiden, barren, 
pregnant and postpartum mares. Although there are 
exceptions, most GCTs are unilateral, benign 
tumors associated with cessation of cyclical 
reproductive activity that is typified by the presence 
of a small, inactive contralateral ovary. Affected 
mares generally exhibit one of three behavioral 
patterns: anestrus, continuous or intermittent estrus 
(i.e., nymphomania), or stallion-like behavior, with 
the type of behavior reflecting the specific tumor 
cell type(s) involved and the attendant steroid 
hormone production (if any). 
 Since GCTs are the only ovarian 
abnormality in the mare characterized by the 
presence of an enlarged ovary that is accompanied 
by inactivity of the contralateral ovary, that clinical 
presentation by itself raises suspicion of a GCT, 
particularly if it is associated with aberrant 
behavior.1 In addition, as the tumor increases in size 
the ovulation fossa is often obliterated, so the 
absence of a palpable ovulation fossa becomes an 
additional finding on physical examination that is 
consistent with a GCT. Ultrasonographically, the 
appearance of the affected ovary can be quite 
variable, ranging from multi-cystic to solid to large 
solitary cystic masses. Clinical diagnosis of a GCT 
requires endocrine testing in order to differentiate 
them from other ovarian tumor types or other causes 
of ovarian enlargement such as an anovulatory 
hemorrhagic follicle or ovarian hematoma.1 
Assessment of testosterone and inhibin levels has 
been the primary endocrine method of detecting 
GCTs, since when they are used together, 
testosterone and inhibin are diagnostic for 
approximately 95% of GCTs.1,2 Importantly 
however, mares that display anestrus or persistent 
estrus usually have normal testosterone levels and 
inhibin levels may not be elevated in the early 
stages of GCT formation requiring additional time 
and expense for repetitive sampling before one or 
both hormones becomes diagnostically elevated. In 
addition, testosterone and inhibin are both elevated 
in pregnant mares, making their interpretation in 
pregnant mares difficult. Because of these 
limitations of inhibin and testosterone testing, 
additional endocrine methods of diagnosing GCTs 
would be clinically useful. 
 Assessment of Anti-Müllerian Hormone 
(AMH) level has recently been validated as an 
additional diagnostic test for GCTs, as evidenced by 
the finding that for 44 GCTs verified by 
histopathology, the sensitivity of detection for 
AMH was 98%, compared to sensitivities of 80% 
for inhibin, 48% for testosterone and 84% when 
inhibin and testosterone were combined.3 Based 
upon immunohistochemistry, AMH is expressed in 
the granulosa cells of normal equine ovaries as well 
as GCTs.4 In a study of circulating AMH levels in 
normal cycling mares, pregnant mares and mares 
with histologically confirmed GCTs, AMH 
concentrations did not differ between normal 
cycling and pregnant mares, and there were no 
significant changes in AMH concentrations during 
the estrous cycle or during pregnancy.5 In contrast, 
AMH was elevated (compared to normal cycling 
and pregnant mares) in all 11 mares with confirmed 
GCTs and the level of AMH declined after surgical 
removal of the tumor.5 Collectively, these studies 
confirm that systemic levels of AMH are elevated in 
mares with GCTs, and determination of AMH 
concentration is a more sensitive method of 
detecting GCTs compared to the assessment of 
inhibin and/or testosterone. In addition, unlike 
inhibin and testosterone, interpretation of 
AMH level is not confounded by stage of the 
estrous cycle or pregnancy. Therefore, 
determination of the AMH level can facilitate 
the diagnosis of a GCT. 
 
Clinical Use of AMH Testing 
 A recent clinical case exemplifies the 
value of determining AMH levels when 
presented with a presumptive GCT.6 A 2-year-
old Quarter Horse filly was retired from race 
training in the fall of 2012 and placed under 
artificial lighting in preparation for breeding 
in 2013. Transrectal palpation and 
ultrasonography were performed in January to 
assess the status of the filly's reproductive 
tract. Examination revealed the left ovary was 
small (31 mm L x 12 mm W x 23 mm H), firm 
and devoid of follicular activity. In contrast, 
the right ovary was considerably larger 
(approximately 70 mm in diameter), lacked a 
palpable ovulation fossa, and was 
characterized ultrasonographically by a large, thick-
walled cavity containing echogenic fluid. The 
uterus and cervix were flaccid, consistent with a 
seasonally anovulatory state, and suggestive that the 
right ovary did not contain functional luteal tissue 
producing progesterone. A stallion was not 
available for assessment of the filly's reproductive 
behavior, but when she was turned out with other 
mares she was behaviorally normal. Although the 
findings of the reproductive examination raised 
suspicion of a tumor of the right ovary, the decision 
was made to delay additional diagnostic testing and 
reexamine the filly in approximately 2 weeks for 
evidence of any notable change in the status of her 
reproductive tract and/or behavior. It was 
anticipated that if the enlargement of the right ovary 
were due to an ovarian tumor, there would be no 
appreciable change in the status of either ovary. In 
contrast, other potential causes of ovarian 
enlargement such as an anovulatory hemorrhagic 
follicle would be more likely to exhibit changes in 
one or both ovaries, such as increased follicular 
activity of the left ovary and/or evidence of 
luteinization within the cavity in the right ovary.  
 
The filly was reexamined 17 days later, at which 
time there was no appreciable change in the status 
of either ovary (Fig. 1), tubular genitalia or 
behavior. Therefore, a tentative diagnosis of a  
 
   
Figure 1. Transrectal ultrasonographic images of the left 
(A) and right (B) ovaries of a 3-year-old Quarter Horse 
filly. The left ovary was small, firm and devoid of 
follicular activity (arrows demarcate outer margins of the 
ovary). The right ovary was approximately 70 mm in 
diameter; lacked a palpable ovulation fossa; and 
consisted of a large, thick-walled cavity containing 
echogenic fluid. Each gradation along the right side of 
the image equals 10 mm. (Reproduced from J Am Vet 
Med Assoc 2013;243:791-793, with permission). 
GCT of the right ovary was made and a jugular 
blood sample was collected for serum endocrine 
testing and submitted to the laboratory that 
developed the equine AMH assay (Figs. 2 and 3).a 
In addition to analyzing a standard “GCT panel” 
that includes inhibin, testosterone and progesterone, 
AMH was analyzed based upon its recent validation 
for use as a diagnostic marker for GCTs. 
  
Fig. 2. Sample preparation guidelines and shipping instructions for testing at the 
Clinical Endocrinology Laboratory at the University of California at Davis. Available 
at: www.vetmed.ucdavis.edu/phr/endolab/index.cfm. (Reproduced with permission).
 
 
  
Fig. 3. Sample submission form for the Clinical Endocrinology Laboratory at the University 
of California at Davis, with options for GCT testing highlighted. For the present case, a GCT 
panel and AMH testing were performed. Form available at: 
www.vetmed.ucdavis.edu/phr/endolab/index.cfm. (Reproduced with permission.) 
  
The endocrine results from the filly are summarized 
in Table 1. As noted, inhibin and testosterone levels 
were borderline elevated and marginally elevated, 
respectively, precluding a definitive diagnosis based 
solely upon those results. In contrast, AMH levels 
were nearly five times above the upper normal 
limit, providing a definitive clinical diagnosis of a 
GCT of the right ovary. 
 
Table 1. Endocrine testing results for a Quarter Horse filly with a presumptive GCT of the right ovary.a 
 
Hormone Test result Reference range Laboratory designation 
Inhibin 0.78 ng/mL 0.1 - 0.7 ng/mL* Borderline elevated 
Testosterone 56.5 pg/mL 20 - 45 pg/mL* Marginally elevated 
AMH 19.0 ng/mL ≤ 4.2 ng/mL Elevated 
Progesterone 0.3 ng/mL < 0.5 ng/mL** Absence of luteal tissue 
* Normal values for a non-pregnant mare. 
** Indicative of the absence of luteal tissue. 
 
 
Based upon the results of the endocrine testing (i.e., 
the elevated AMH level), the affected right ovary 
was surgically removed via colpotomy using a 
chain ecraseur. On gross examination the ovarian 
mass was spherical, 7.5 cm in diameter, white, and 
had a single central cyst filled with viscous yellow 
fluid (Fig. 4). Histopathologically, the cyst wall 
consisted of vascularized fibrous tissue in which 
both granulosa and theca cell components were 
present, confirming the diagnosis of a GCT.7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Photographs of the intact (A) and bisected (B) right ovary of a 3-year-old Quarter Horse filly confirmed 
to be a GCT. Each gradation along the top edge of both images = 1 mm. (Reproduced from J Am Vet Med Assoc 
2013;243:791-793, with permission). 
 
 The filly recovered uneventfully following 
the unilateral ovariectomy procedure and was 
examined with transrectal palpation and 
ultrasonography 29 days after surgery. Examination 
revealed the left ovary was still relatively small, but 
appeared ultrasonographically to contain evidence 
of luteal tissue. In addition, uterine and cervical 
tone were consistent with a progestational effect, 
therefore a jugular blood sample was collected and 
submitted for serum endocrine testing for 
progesterone at the same laboratory.a Blood 
progesterone concentration was 10.9 ng/mL, 
confirming the presence of functional luteal tissue, 
indicating the filly had ovulated since the initial pre-
surgical blood sample was collected. Regarding 
return to cyclicity of the contralateral ovary after 
removal of a GCT, in one report,8 42 of 57 mares 
resumed normal estrous cycles an average of 8.5 
months after surgery (range of 2 to 16 months), and 
in another report,9 8 of 10 mares resumed normal 
estrous cycles during the spring after removal of the 
abnormal ovary. It seems likely the filly in this 
report resumed ovulatory activity of the normal 
ovary so rapidly after removal of the GCT because 
of the early diagnosis associated with use of the 
AMH assay, which allowed removal of the affected 
ovary early enough in the breeding season (in 
conjunction with artificial lighting) to hasten the 
return of ovulatory activity. This is in contrast to a 
“wait and see” approach that would have been 
indicated had only inhibin and testosterone testing 
been performed, which would have delayed 
diagnosis and treatment in this filly. 
 
 In summary, this case exemplifies the 
clinical value of determining AMH levels when 
presented with a presumptive GCT, since neither 
the level of inhibin (borderline elevated) or 
testosterone (marginally elevated) was definitively 
diagnostic at the stage of tumor development when 
endocrine testing was performed. In contrast, the 
level of AMH was unequivocally diagnostic, 
allowing immediate therapeutic removal of the 
affected ovary. 
 
Footnotes 
a Clinical Endocrinology Laboratory, Department of 
Population Health and Reproduction, School of 
Veterinary Medicine, University of California at 
Davis, 4206 VM3A, 1 Shields Avenue, Davis, CA 
95616-5270. 
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